Tumor Infiltrating Lymphocytes (TIL Cells) Transduced With An Interleukin-2 (SBIL-2) Gene Following The Administration Of A Nonmyeloablative But Lymphocyte Depleting Regimen in Metastatic Melanoma.

Trial Profile

Tumor Infiltrating Lymphocytes (TIL Cells) Transduced With An Interleukin-2 (SBIL-2) Gene Following The Administration Of A Nonmyeloablative But Lymphocyte Depleting Regimen in Metastatic Melanoma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Tumour infiltrating lymphocytes (Primary) ; Filgrastim
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Mar 2012 New trial record
    • 26 Mar 2012 New trial record
    • 17 Jul 2007 Planned number of patients 33 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top